Expert review of respiratory medicine最新文献_第3页

Time for proper physiological assessment: the role of cardiopulmonary exercise testing in helping step-up therapy in difficult-to-treat and severe asthma. 适当的生理评估时间：心肺运动试验在帮助加强治疗难治性和重度哮喘中的作用。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-04-07 DOI: 10.1080/17476348.2026.2656470

Ariel Fabian Floriani, Francesco Menzella

{"title":"Time for proper physiological assessment: the role of cardiopulmonary exercise testing in helping step-up therapy in difficult-to-treat and severe asthma.","authors":"Ariel Fabian Floriani, Francesco Menzella","doi":"10.1080/17476348.2026.2656470","DOIUrl":"10.1080/17476348.2026.2656470","url":null,"abstract":"Introduction: Persistent exertional dyspnea remains a major unmet need in patients with difficult-to-treat and severe asthma, even in the era of optimized inhaled therapy and biologics. Resting lung function and inflammatory biomarkers often fail to explain exercise intolerance, leading to empirical step-up therapy without clear physiological justification.Areas covered: This review discusses the role of cardiopulmonary exercise testing (CPET) in the evaluation of exertional dyspnea in difficult-to-treat and severe asthma, within the treatable traits framework. The review focuses on the main CPET-derived physiological patterns, including ventilatory limitation, dynamic hyperinflation, ventilatory inefficiency, dysfunctional breathing, deconditioning, cardiovascular limitation, exercise-induced laryngeal obstruction, and normal exercise physiology. It also examines how CPET may influence step-up decisions, support trait-directed interventions, and inform pharmacoeconomic considerations. A pragmatic clinical framework for selective integration of CPET into severe asthma assessment is proposed.Expert opinion: CPET may represent a valuable physiological adjunct in selected patients with difficult-to-treat or severe asthma and persistent exertional dyspnea insufficiently explained by resting assessments. Its integration into the assessment pathway may help contextualize symptoms, distinguish asthma-driven exercise limitation from non-inflammatory or non-asthmatic causes of dyspnea, and support more mechanism-based management. However, current evidence supports CPET primarily as a tool for physiological phenotyping and trait reclassification rather than as a prospectively validated guide to treatment escalation, biologic stewardship, or long-term outcome improvement.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"963-974"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147611030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies. 环境变化中的呼吸健康：适应环境的疗法和修订的给药策略。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-04-23 DOI: 10.1080/17476348.2026.2659383

Mario Cazzola, Raffaella Pagliaro, Alfredo De Biase, Andrea Bianco, Maria Gabriella Matera, Vincenzo Patella

{"title":"Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies.","authors":"Mario Cazzola, Raffaella Pagliaro, Alfredo De Biase, Andrea Bianco, Maria Gabriella Matera, Vincenzo Patella","doi":"10.1080/17476348.2026.2659383","DOIUrl":"10.1080/17476348.2026.2659383","url":null,"abstract":"Introduction: Chronic airway diseases, such as asthma and COPD, are major contributors to global morbidity and the healthcare burden. Due to their heterogeneity and sensitivity to environmental factors, including air pollution, tobacco smoke, and occupational exposures, they are critical models for examining how the environment shapes disease biology and treatment response.Areas covered: This expert narrative review integrates mechanistic, clinical, and epidemiological evidence on the impact of environmental exposures on the biology of airway disease and therapeutic outcomes. A structured literature search was performed, prioritizing mechanistic studies, large cohorts, randomized trials, and high-quality reviews relevant to asthma and COPD endotypes, phenotypes, and environment-adaptive therapies. The evidence indicates that environmental exposures modulate inflammatory pathways, oxidative stress, and drug responsiveness. These exposures often account for variability in clinical outcomes and apparent treatment resistance.Expert opinion: Environmental exposures should be recognized as core biological modifiers that directly impact therapeutic efficacy, dosing requirements, and safety. Incorporating a systematic approach to environmental assessment into precision respiratory medicine allows for environment-adaptive therapies, optimizes pharmacological interventions, and reduces the risk of overtreatment. Future research and clinical protocols should integrate exposure metrics to personalize therapy, improve symptom control, and enhance long-term outcomes for patients with asthma and COPD.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1019-1037"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147694315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telemedicine-driven rehabilitation in interstitial lung diseases: a narrative review. 远程医疗驱动的间质性肺疾病康复：叙述性回顾。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-02-28 DOI: 10.1080/17476348.2026.2637923

Sanghoon Park, Sue In Choi, Eun Joo Lee

{"title":"Telemedicine-driven rehabilitation in interstitial lung diseases: a narrative review.","authors":"Sanghoon Park, Sue In Choi, Eun Joo Lee","doi":"10.1080/17476348.2026.2637923","DOIUrl":"10.1080/17476348.2026.2637923","url":null,"abstract":"Introduction: Telemedicine is defined as the delivery of healthcare from a distance using electronic information and communication technology. Patients with interstitial lung disease (ILD) were among the early recipients of such remote healthcare.Areas covered: We reviewed this contemporary field of telemedicine-driven therapeutic interventions in ILD patients. PubMed was used for literature search, focusing on research articles, international guidelines, and so on.Expert opinion: The initial stage of telemedicine for ILD patients was mainly focused on subjects already diagnosed and was therefore adopted for monitoring purposes. As technology developed, pulmonary rehabilitation (PR) also became amenable to remote delivery to evaluate therapeutic efficacy of home-based interventions. Physicians are enabling ILD patients to undergo therapeutic PR at home, with the support of telemedicine. This approach is being tested across various ILD diseases, showing promising results. Telemedicine presents an opportunity to reduce the socioeconomic burden on both patients and caregivers during therapeutic rehabilitation of ILD patients. This potential, however, is contingent upon successfully addressing challenges like legal issues and ensuring high user adoption.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"913-923"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From lungs to brain: the neuroimmune impact of respiratory microbiota. 从肺到脑：呼吸微生物群的神经免疫影响。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-03-24 DOI: 10.1080/17476348.2026.2648109

Khiany Mathias, Victoria Linden de Rezende, Anita Dal Bó Tiscoski, Larissa Dallefe, Felipe Dal-Pizzol, Tatiana Barichello, Fabricia Petronilho

{"title":"From lungs to brain: the neuroimmune impact of respiratory microbiota.","authors":"Khiany Mathias, Victoria Linden de Rezende, Anita Dal Bó Tiscoski, Larissa Dallefe, Felipe Dal-Pizzol, Tatiana Barichello, Fabricia Petronilho","doi":"10.1080/17476348.2026.2648109","DOIUrl":"10.1080/17476348.2026.2648109","url":null,"abstract":"Introduction: The bidirectional communication between the lungs and the central nervous system, known as the lung-brain axis, has emerged as an important framework for understanding systemic mechanisms influencing neurological health. Increasing evidence indicates that pulmonary inflammation, respiratory microbiota alterations, and environmental exposures can modulate neuroinflammation, blood-brain barrier integrity, and microglial activation.Areas covered: This review summarizes current experimental and clinical evidence describing the molecular, microbial, and neuroimmune mechanisms underlying the lung-brain axis. Particular emphasis is placed on the role of the respiratory microbiota across the upper and lower airways and its interaction with immune signaling pathways. In addition, the neurological consequences of pulmonary diseases and infections, including asthma and COVID-19, are discussed, highlighting neuroanatomical, humoral, and immunological routes linking pulmonary and brain physiology.Expert opinion: Emerging data suggest that the respiratory system functions as an immunometabolic interface capable of influencing neuroimmune regulation and brain function. Integrative approaches combining respiratory microbiota profiling, immune biomarkers, and neuroimaging may help clarify causal mechanisms and support the development of novel diagnostic and therapeutic strategies for neurological and post-infectious conditions.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"993-1002"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease: advances, challenges, and future directions. 吸入曲前列地尼治疗与间质性肺病相关的肺动脉高压：进展、挑战和未来方向

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-04-23 DOI: 10.1080/17476348.2026.2661412

Marianne Riou, Léon Genecand, Matthieu Canuet, Tristan Dégot, Xavier Jaïs, Marie-Camille Chaumais, Etienne-Marie Jutant, David Montani

{"title":"Inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease: advances, challenges, and future directions.","authors":"Marianne Riou, Léon Genecand, Matthieu Canuet, Tristan Dégot, Xavier Jaïs, Marie-Camille Chaumais, Etienne-Marie Jutant, David Montani","doi":"10.1080/17476348.2026.2661412","DOIUrl":"10.1080/17476348.2026.2661412","url":null,"abstract":"Introduction: Inhaled treprostinil (iTre) has recently emerged as a therapeutic option for severe pulmonary hypertension associated with interstitial lung disease (PH-ILD), combining pulmonary vasodilatory, antiproliferative, and potential anti-fibrotic effects, while minimizing systemic exposure and ventilation-perfusion mismatch.Areas covered: This review provides a comprehensive overview of iTre in PH-ILD, including its mechanisms of action, clinical efficacy, safety profile, and emerging applications in fibrotic ILD.Expert opinion: The phase 3 INCREASE study demonstrated improvements in exercise capacity, reduction in N-terminal pro-brain natriuretic peptide levels, and attenuation of clinical worsening events with iTre. Post-hoc analyses suggest potential benefits on lung function and ILD exacerbations, particularly in idiopathic pulmonary fibrosis, while efficacy appears less pronounced in combined pulmonary fibrosis and emphysema or in patients with milder pulmonary vascular disease. iTre is generally well tolerated, with airway-related adverse events most common, and systemic effects limited. Emerging long-acting and dry-powder inhaled formulations aim to improve adherence, reduce dosing frequency, and extend the therapeutic potential to fibrotic ILD without PH. iTre has thus emerged as the first targeted therapy for PH-ILD, with unique pharmacological and biological properties. Remaining challenges include optimal patient selection, confirmation of long-term benefits, and integration with antifibrotic or other pulmonary vasodilator therapies.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"975-991"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in biologic therapies for COPD: precision medicine approaches and implications for small-airway disease. 慢性阻塞性肺病的生物治疗进展：精准医学方法及其对小气道疾病的影响。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-03-12 DOI: 10.1080/17476348.2026.2644609

Sumbul Afreen, Maddison Waters, Mathew Suji Eapen, Wenying Lu, Md Imtaiyaz Hassan, Sukhwinder Singh Sohal

{"title":"Advances in biologic therapies for COPD: precision medicine approaches and implications for small-airway disease.","authors":"Sumbul Afreen, Maddison Waters, Mathew Suji Eapen, Wenying Lu, Md Imtaiyaz Hassan, Sukhwinder Singh Sohal","doi":"10.1080/17476348.2026.2644609","DOIUrl":"10.1080/17476348.2026.2644609","url":null,"abstract":"Introduction: COPD is a progressive respiratory condition marked by persistent airflow limitation and chronic inflammation, mainly caused by cigarette smoking. Although current inhaled therapies improve symptoms and reduce exacerbations, they do not substantially modify disease progression, emphasizing the need for novel therapeutic approaches.Areas covered: This review provides a comprehensive overview of the effectiveness and mechanisms of biologic therapies in the management of COPD. We discuss the mechanistic rationale, clinical efficacy, and limitations of currently approved and emerging biologics, highlighting their relevance to distinct inflammatory endotypes of COPD. The role of small-airway disease in COPD is highlighted, together with advances in drug formulation and inhaled delivery technologies. Challenges related to drug delivery, particularly the influence of particle size on distal airway deposition, are examined, along with recent innovations in nanotechnology and comparative considerations of systemic versus inhaled therapeutic approaches. Relevant literature was identified through searches of PubMed (MEDLINE), Embase, Web of Science, and Google Scholar. Studies available in print or online up to June 2025 were considered.Expert opinion: Biologic therapies offer promise for selected COPD phenotypes; however, their long-term impact will depend on precision medicine, optimized airway-targeted delivery, and integration with established inhaled treatments to achieve meaningful disease modification.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"925-942"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daytime sleepiness in patients with obstructive sleep apnea and associated comorbidities. 阻塞性睡眠呼吸暂停患者的日间嗜睡及相关合并症

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-03-30 DOI: 10.1080/17476348.2026.2651412

Claudia Di Chiara, Giulia Sartori, Nadia Castaldo, Alberto Fantin, Marcello Ferrari, Ernesto Crisafulli

{"title":"Daytime sleepiness in patients with obstructive sleep apnea and associated comorbidities.","authors":"Claudia Di Chiara, Giulia Sartori, Nadia Castaldo, Alberto Fantin, Marcello Ferrari, Ernesto Crisafulli","doi":"10.1080/17476348.2026.2651412","DOIUrl":"10.1080/17476348.2026.2651412","url":null,"abstract":"Introduction: Obstructive sleep apnea (OSA) is characterized by recurrent upper-airway collapse during sleep, leading to ineffective respiratory efforts, intermittent hypoxia, and sleep fragmentation. Patients with OSA often have comorbid conditions. Excessive daytime sleepiness (EDS), defined as an inability to remain awake during the day, is common among patients with OSA; however, its perception may vary with comorbidities that affect autonomic and neuroendocrine regulation.Areas covered: We reviewed studies examining the prevalence and clinical impact of EDS in patients with OSA and its main comorbidities, published between January 2000 and September 2025, and identified through Medline.Expert opinion: EDS is highly prevalent in patients with OSA and arterial hypertension, cardiac arrhythmias, cerebrovascular comorbidities (particularly in those with thalamic or pontine lesions), diabetes mellitus, metabolic syndrome, asthma, chronic kidney disease, and cancer. By contrast, EDS appears less prevalent in patients with heart failure, treated cerebrovascular and neurodegenerative disease (particularly in those receiving levodopa, selective serotonin reuptake inhibitors, or bromocriptine), and chronic obstructive pulmonary disease (COPD).In conclusion, in patients with OSA, EDS is perceived differently depending on comorbidity. Consequently, EDS assessment should follow a personalized, multidimensional approach that recognizes its clinical relevance while accounting for variability across comorbid conditions.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1003-1017"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and future contributions of AI to pulmonary function test interpretation, diagnostic approaches, and predictions of disease progression. 人工智能对肺功能测试解释、诊断方法和疾病进展预测的当前和未来贡献。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-03-26 DOI: 10.1080/17476348.2026.2647482

Hà Pham-Ngoc, Thông Hua-Huy, Oanh Thi Tuong Do, Lê-Quyên Thi Pham, Nhu-Vinh Nguyen, Thu-Phuong Phan, Tuyêt-Lan Thi Lê, Tien-Zung Nguyen, Anh Tuan Dinh-Xuan

{"title":"Current and future contributions of AI to pulmonary function test interpretation, diagnostic approaches, and predictions of disease progression.","authors":"Hà Pham-Ngoc, Thông Hua-Huy, Oanh Thi Tuong Do, Lê-Quyên Thi Pham, Nhu-Vinh Nguyen, Thu-Phuong Phan, Tuyêt-Lan Thi Lê, Tien-Zung Nguyen, Anh Tuan Dinh-Xuan","doi":"10.1080/17476348.2026.2647482","DOIUrl":"10.1080/17476348.2026.2647482","url":null,"abstract":"Introduction: Artificial intelligence (AI) methods - including machine learning, deep learning, and explainable AI - are increasingly applied to pulmonary function testing (PFT) to enhance interpretation, standardize procedures, and support clinical decision-making.Areas covered: This narrative review synthesizes evidence on AI contributions to diagnostic classification, quality control, signal analysis, and predictive modeling in PFT. AI systems have demonstrated improved accuracy and reproducibility versus unaided clinicians for tasks such as ventilatory pattern classification, small-airway dysfunction detection, methacholine challenge prediction, and automated spirometry quality assessment. Explainable AI methods increase clinician trust and interreader concordance. Key limitations include variable algorithm performance, limited interpretability, dependence on the quality and representativeness of training data, and insufficient integration of comprehensive clinical context. Priority development areas are assembling large, diverse, and standardized datasets aligned with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines; implementing bias detection and mitigation strategies; defining clinically meaningful endpoints for validation; advancing explainability frameworks; and ensuring interoperability across PFT platforms.Expert opinion: Multidisciplinary collaboration among clinicians, engineers, and information technology specialists is essential for safe, ethical, and effective deployment. AI is a powerful adjunct for PFT interpretation but should remain a decision support tool pending rigorous real-world validation.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"943-952"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathological roles of transient receptor potential channels in chronic obstructive pulmonary disease: special focus on cellular mechanisms. 瞬时受体电位通道在慢性阻塞性肺疾病中的病理作用：特别关注细胞机制。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-03-30 DOI: 10.1080/17476348.2026.2652117

Yi-Ran Ye, Yu-Yun Zhou, Su Qu, Wen-Liang Zhou, Lei Chen, Yi-Lin Zhang

{"title":"Pathological roles of transient receptor potential channels in chronic obstructive pulmonary disease: special focus on cellular mechanisms.","authors":"Yi-Ran Ye, Yu-Yun Zhou, Su Qu, Wen-Liang Zhou, Lei Chen, Yi-Lin Zhang","doi":"10.1080/17476348.2026.2652117","DOIUrl":"10.1080/17476348.2026.2652117","url":null,"abstract":"Introduction: Transient receptor potential (TRP) channels comprise a superfamily of cation-permeable channels broadly expressed in the respiratory tract, playing essential roles in regulating epithelial integrity, mucus secretion, mechanotransduction, and innate immune responses. Increasing evidence suggests that dysregulation of TRP channels contributes to the pathogenesis of chronic obstructive pulmonary disease (COPD).Areas covered: This review summarizes current insights into the cellular mechanisms by which TRP channels contribute to COPD, with particular emphasis on respiratory epithelial dysfunction while also incorporating selected non-epithelial mechanisms relevant to disease pathogenesis. A comprehensive literature search was conducted in PubMed and Web of Science up to January 2026.Expert opinion: Evidence for TRP involvement in COPD is heterogeneous. TRPV4 currently has the strongest mechanistic and translational support, whereas TRPC1 and TRPC6 still require further therapeutic validation. TRPV2 appears to be linked more specifically to macrophage dysfunction and emphysema-related pathology, whereas the roles of TRPV6 and TRPM6 are still incompletely defined. A key barrier to clinical translation is that numerous TRP-targeted strategies have been developed outside COPD or have shown limited efficacy in the clinical settings tested to date, while safety concerns also remain. Future progress will require COPD-specific validation, localized delivery, and biomarker-guided treatment strategies matched to defined disease phenotypes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"953-962"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147523248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From ideal respiratory health to chronic lung disease: indicators of impaired respiratory health. 从理想的呼吸系统健康到慢性肺病：呼吸系统健康受损的指标。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-01 Epub Date: 2026-03-03 DOI: 10.1080/17476348.2026.2637202

Kavitha C Selvan, Joseph I Bailey, Ravi Kalhan

{"title":"From ideal respiratory health to chronic lung disease: indicators of impaired respiratory health.","authors":"Kavitha C Selvan, Joseph I Bailey, Ravi Kalhan","doi":"10.1080/17476348.2026.2637202","DOIUrl":"10.1080/17476348.2026.2637202","url":null,"abstract":"Introduction: Ideal respiratory health and chronic respiratory disease exist on a continuum. Between these two extremes lies an intermediate state of impaired respiratory health, characterized by clinical phenotypes that exist along the causal pathway. Identifying individuals with intermediate phenotypes of impaired respiratory health offers an opportunity to intercept progression to chronic respiratory disease.Areas covered: In this review, we identify parameters associated with impaired respiratory health, including respiratory symptoms and illnesses, abnormal lung physiology, imaging abnormalities, and blood biomarkers. We then synthesize evidence linking these parameters to future respiratory impairment.Expert opinion: Drawing inspiration from advances in cardiovascular disease prevention, the respiratory field must adopt a holistic framework that considers the likely shared biologic mechanisms underpinning chronic lung diseases. Effective disease prevention depends on a multi-omic approach that integrates clinical, physiologic, imaging, and molecular data to identify individuals at increased risk for chronic respiratory disease. Prospective evaluation of these at-risk individuals can be utilized to evaluate the impact of targeted preventative strategies.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"901-912"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13289706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0